Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.

Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be ...

Around half of all cutaneous melanomas carry a BRAF mutation, with the majority of these being V600E. (Nasekom/iStock/Getty Images Plus) The FDA has signed off on Labcorp’s companion diagnostic for ...

Dirk Schadendorf, MD, discusses where triplet therapy fits for BRAF V600-mutant melanoma following the results of the STARBOARD trial.

Two BRAF-targeted agents already used together in several solid tumors have won parallel regulatory support in Europe. In its March 2026 meeting, the European Medicines Agency’s Committee for ...

Newswise — Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical ...

The optimal treatment sequence in non-small cell lung cancer harboring class I BRAF mutations and atypical BRAF variants remains unclear. To better characterize therapeutic strategy, we ...

A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...

(Top) Melanoma develops resistance to BRAF inhibitors, leading to cancer recurrence. (Bottom) By combining polyamine biosynthesis inhibition with BRAF inhibitors, the recurrence of cancer can be ...

“Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression” “Inhibitors ...

Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in ...